Traws Pharma submits Phase 2 protocols for bird flu and COVID drugs; requests FDA meeting

Traws Pharma, Inc.

Submitted HREC Phase 2 protocol for tivoxavir marboxil (TXM) to treat H5N1 bird flu and seasonal influenza.
Submitted Type D FDA meeting request to discuss accelerated approval for TXM under the Animal Rule.
Submitted HREC Phase 2 protocol for ratutrelvir in acute COVID, including PAXLOVID-ineligible patients, with rebound and Long COVID assessments.
Cash and equivalents of $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.
Continuing discussions with BARDA regarding strategic stockpile inclusion for TXM.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.